Company Overview
Scholar Rock Holding Corporation operates as a biopharmaceutical entity dedicated to advancing treatments for spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company functions within the healthcare sector and specifically the biotechnology industry, focusing on novel understandings of the molecular mechanisms of growth factor activation to improve patient outcomes. This organization employs a workforce of 289 individuals and maintains a market capitalization of $5.23 billion. While the company reports a negative annual revenue figure listed as N/A in its current financial reporting, the market cap indicates a significant valuation assigned by the market, suggesting that investors are pricing the entity based on future potential rather than current profitability. This substantial market valuation relative to the lack of reported revenue highlights the company's position as an asset-light biotechnology firm where value is derived from intellectual property and pipeline development rather than immediate sales volume.
Financial Health
The company reports a Net Income (TTM) of $-377,939,008 and an EBITDA of $-382,987,008, with revenue growth and earnings growth data listed as N/A. The gap between the reported revenue (N/A) and the substantial net loss reveals a cost structure heavily weighted toward research and development expenditures typical of early-stage biotechnology firms, where operating expenses significantly exceed any generated revenue. Scholar Rock Holding Corporation generated Free Cash Flow of $-162,622,256, indicating that the company is currently burning cash to fund its operations and drug discovery efforts rather than generating surplus liquidity. All three reported margin metrics—Gross Margin, Operating Margin, and Profit Margin—are listed as 0.0%, which mathematically reflects the absence of positive revenue or indicates that costs are consuming all available income, resulting in zero percentage profitability on a historical basis. The company holds Cash of $367.56M against Debt of $108.92M, resulting in a Debt to Equity ratio of 44.37, which suggests a balance sheet that is leveraged but supported by significant cash reserves to service obligations. The Current Ratio stands at 6.95, indicating a highly conservative short-term liquidity position where current assets are nearly seven times greater than current liabilities. Return on Equity is -123.1% and Return on Assets is -54.7%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets, reflecting the long-term investment phase of the biotechnology sector.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the lack of positive earnings, while the Forward P/E is -20.69, a negative figure that implies expected earnings are currently negative and the market is not pricing in immediate profitability. The Price to Book ratio is 20.11, indicating that the market values the company at a significant premium over its tangible book value, a common characteristic for firms with valuable intangible assets like drug patents. The Price to Sales ratio is N/A and the EV/EBITDA is -12.97, suggesting that traditional revenue-based or earnings-based valuation multiples are not applicable in their standard positive forms, forcing reliance on asset-heavy or pipeline-based valuation models. The 52-Week High is $49.82 and the 52-Week Low is $22.71; without a specific current price provided in the facts, the range establishes a volatility corridor of $27.11 between the recent high and low. The Beta is 0.75, meaning the stock's price volatility is theoretically lower than the broader market, moving less dramatically than the S&P 500 during periods of market fluctuation.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, indicating that historical year-over-year expansion rates are not currently disclosed or are negligible given the N/A revenue figure. Since the company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, the organization reinvests all available earnings and cash reserves directly into research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of dividend income and a reliance on capital markets for funding, rather than organic earnings growth or cash flow generation at this stage. The financial data confirms a profile typical of clinical-stage biotechnology companies where growth is measured in pipeline progression and regulatory milestones rather than traditional financial statement expansion.